article
Drug Target Review – Issue #3 2016
20 September 2016 | By Drug Target Review
In Issue #3 2016: Flow Cytometry, Enzymes, Imaging, GPCRs, Hit-To-Lead, CNS, Companion Diagnostics, and much more...
List view / Grid view
Issue #3 2016
article
Imaging In-Depth Focus 2016
In this Imaging In-Depth Focus: Norman Peterson, from MedImmune/AstraZeneca, looks at the practical application of in vivo optical imaging in biotherapeutic biodistribution analyses. Plus, experts from MRC Technology discuss high-content imaging in drug discovery, and Molecular Devices feature in our Q&A...
article
Hit-To-Lead In-Depth Focus 2016
20 September 2016 | By Drug Target Review
In this Hit-To-Lead In-Depth Focus: Hit-to-lead in drug discovery; Zebrafish early-life stages as neurological screening and detection tools...
article
Under the microscope with Joseph Zock, IntelliCyt Corporation
20 September 2016 | By Drug Target Review
Drug Target Review talks to Joseph Zock, Senior Director of Product Management at IntelliCyt Corporation, to find out more about assay developments and future innovations in this area of drug discovery...
article
Under the microscope with Dr Jeffrey A. Borgia, Rush University Medical Center
Researchers at Rush Medical Center are developing novel diagnostic tests to help guide treatment decisions for patients with non-small cell lung cancer...
article
Product Showcase: End-to-end next-generation sequencing for clinical diagnostics
20 September 2016 | By Vela Diagnostics
Fuelled by the rapid development of next-generation sequencing (NGS) technologies, it has become apparent that the technology is a key for the identification of genetic variants...
article
Flow cytometry: breaking bottlenecks in drug discovery and development
The discovery and development of novel drug candidates is a highly complex, time-consuming and expensive process. Pharmaceutical scientists and clinicians should, therefore, reevaluate and modify the existing standard platforms and increase their uptake of robust advanced technologies such as flow cytometry to overcome the bottlenecks in these processes...
article
Switching on genes regulating oxysterol synthesis – a therapeutic option?
Cholesterol is a ubiquitous molecule that, while essential for health, is probably best known as a risk factor for cardiovascular disease. It is also the obligate precursor for a wide range of metabolites, from steroid hormones to bile acids. Although studied for more than 100 years, recently there has been…
article
High-throughput calcium flux assays: luminescent versus fluorescent readout
In vitro high-throughput cellular target-based assays are commonly used for hit identification targeting G-protein coupled receptors (GPCR). Agonist and antagonist identification of GPCRs often relies on the screening of large collections of chemicals using miniaturised in vitro cell-based functional assays. In the panel of assays, calcium mobilisation measured by aequorin…
article
Fibromyalgia pathogenesis provides drug target clues
Fibromyalgia (FM) has been described as a condition of heightened generalised sensitisation to sensory input presenting as a complex of symptoms dominated by chronic widespread pain characterised by hyperalgesia and allodynia. A range of co-morbidities of variable intensity, such as fatigue, sleep disturbance, cognitive impairment, anxiety and depression, are often…
article
A picture is worth a thousand endpoints: high-content imaging in drug discovery
Over the past few years several factors in the drug discovery industry have come together to drive an increased interest and subsequent surge in the use of high-content imaging. These include the high costs of attrition in the clinic due to lack of efficacy; increased hurdles and rising costs to…
article
Zebrafish early-life stages as neurological screening and detection tools
Unforeseen efficacy and safety-related issues with drugs continue to be a major cause of their attrition, despite significant efforts that are expended to eliminate them prior to initiating clinical trials...
article
Hit-to-lead in drug discovery
Starting in the 1970s, the drug discovery research process changed dramatically. Our understanding of biological targets and pathways grew and the largely empirical and target agnostic in vivo pharmacology approach was replaced with target-centric methods...